Our team is diverse in background and expertise, but are all driven and motivated by one thing: serving patients. The team brings together decades of experience across many disciplines to accelerate the development and delivery of innovative gene therapies with the hopes of transforming patient lives.


Pavan Cheruvu, MD, is Axovant’s Chief Executive Officer. Dr. Cheruvu previously held roles of increasing responsibility at Roivant Sciences and was appointed to the company’s executive leadership team in 2017. He supported Axovant in numerous capacities throughout his tenure at Roivant. A board-certified physician, Dr. Cheruvu completed his residency in internal medicine at Johns Hopkins Hospital and continued his training in a clinical fellowship in cardiovascular medicine at the University of California, San Francisco. Prior to his medical training, Dr. Cheruvu was a management consultant at McKinsey & Company, where he focused on biopharmaceutical strategy. Dr. Cheruvu earned his B.S.E. in biomedical engineering, B.S.E. in electrical engineering, and A.B. in chemistry summa cum laude from Duke University, obtained his M.Sc. in computer science as a Rhodes Scholar at Oxford University, and obtained his M.D. from Harvard Medical School.

Pavan Cheruvu, MD — Chief Executive Officer

Gavin Corcoran, MD joined Axovant as Chief R&D Officer. In his career, he has overseen successful drug development across multiple therapeutic areas, including neurology and psychiatry, and was previously Chief Medical Officer of Allergan plc and Actavis. Dr. Corcoran was Executive Vice President for Global Medicines Development at Forest Laboratories prior to the acquisition of Forest Laboratories by Actavis. Dr. Corcoran also served as Head of Late Stage Clinical Development for Inflammation and Immunology at Celgene, and as Chief Scientific Officer and head of R&D at Stiefel Laboratories. Earlier in his career he held leadership roles in clinical development and regulatory affairs at Amgen, Schering-Plough, and Bayer. He received his MB BCh from the University of the Witwatersrand in South Africa and completed his clinical training in internal medicine and infectious diseases at the University of Texas Health Science Center at San Antonio.

Gavin Corcoran, MD — Chief R&D Officer

Fraser Wright, PhD, serves as Chief Technology Advisor, overseeing Axovant’s gene therapy initiatives. Dr. Wright is the Co-Founder and former Chief Technology Officer of Spark Therapeutics and has over 20 years of leadership experience in the development of novel vector-based biologic products. At Spark, he oversaw process development and clinical-stage manufacturing for LUXTURNA™. Prior to Spark, Dr. Wright was the founding Scientific Director of the Clinical Vector Core Laboratory at The Children’s Hospital of Philadelphia, where he directed clinical core staff in gene therapy investigational product development, manufacture, and quality control testing for ten first-in-human viral vector investigational products including LUXTURNA™ and Kymriah®. He was also previously the Director of Development and Clinical Manufacturing at Avigen. Dr. Wright is a former Research Professor of Pathology and Laboratory Medicine at the University of Pennsylvania School of Medicine, and he is the lead inventor on numerous issued patents during his time in that role. He received his BSc and PhD in biochemistry from the University of Toronto, where he was also an assistant professor of biochemistry and medicine.

Fraser Wright, PhD — Chief Technology Advisor

David Nassif, JD, serves as Chief Financial Officer at Axovant. He has more than 25 years of life sciences industry experience in executive financial management roles in development-stage, commercial-stage, public and private companies. Prior to joining Axovant, Mr. Nassif was Executive Vice President and Chief Financial Officer of SteadyMed Therapeutics, where he was instrumental in its acquisition by United Therapeutics in August 2018. From 2011 to 2014, Mr. Nassif served as the President and Chief Financial Officer of Histogen. Previously, he was Executive Vice President and Chief Financial Officer of Zogenix and held several key roles at Amphastar Pharmaceuticals and RealAge Inc. Earlier in his career, Mr. Nassif held various positions with Cypros Pharmaceuticals, where he was instrumental in leading its merger with Ribogene, Inc. to form Questcor Pharmaceuticals, Inc. He holds a B.S. in Finance and Management Information Systems with honors from the University of Virginia and a J.D. from the University of Virginia School of Law.

David Nassif, JD — Chief Financial Officer

Parag Meswani, PharmD, joins Axovant as senior vice president of commercial strategy and operations. Dr. Meswani has over 17 years of experience in the biopharma industry, having served in various commercial and medical affairs leadership roles at Novartis, Pharmacia, Biogen, and most recently, Spark Therapeutics. At Spark, he served as head of U.S. marketing and diagnostics, leading the development and execution of the brand strategy for LUXTURNA™. Prior to Spark, Dr. Meswani held several corporate and franchise leadership roles at Biogen, including serving in the office of the CEO, commercial operations, the multiple sclerosis franchise and the U.S. hemophilia franchise. Dr. Meswani earned his M.B.A. from Columbia University and his Pharm.D. and B.S. from the Ernest Mario School of Pharmacy at Rutgers University.

Parag Meswani, PharmD — Senior Vice President, Commercial Strategy and Operations

Paul Korner, MD, MBA, joins Axovant as senior vice president of clinical development. Dr. Korner has 20 years of experience in clinical development and medical affairs, most recently serving as vice president of medical strategy and clinical development at Sarepta Therapeutics focusing on the development of precision genetic medicines focused on rare neuromuscular diseases. Prior to Sarepta, he held executive-level roles at Ardelyx and Ferring Pharmaceuticals, where he was involved in the FDA approval of seven programs and the execution of 44 local and global studies. Prior to Ferring, Dr. Korner held several roles in clinical development and medical affairs at Bayer, Wyeth (now Pfizer) and Solvay. Dr. Korner received his M.D. from Loyola University, his M.B.A. from Kennesaw State University and his B.S. in biology with honors from the University of Illinois.

Paul Korner, MD, MBA — Senior Vice President, Clinical Development & Medical Affairs

Greg Stewart, Ph.D., joins Axovant as senior vice president of vector delivery and optimization with responsibility for ongoing clinical refinement of Axovant’s gene therapy programs. Dr. Stewart has over 25 years of experience in drug development for neurological conditions from preclinical discovery to phase 2/3 clinical trials, most recently serving as chief scientific officer at Pairnomix. Prior to Pairnomix, he was vice president of vector delivery at Voyager Therapeutics, where he directed research to optimize targeted delivery of viral vectors to the brain and spinal cord for the treatment of neurodegenerative disease. Dr. Stewart has also held various scientific and development roles at Medtronic, Genzyme, ALZA and Roche and served as a fellow at the National Institute of Mental Health. He received his Ph.D. in neural sciences from Washington University in St. Louis and his B.S. in neuroscience from Texas Christian University.

Greg Stewart, PhD — Senior Vice President, Vector Delivery and Optimization

Sean O’Bryan joins Axovant as vice president of regulatory affairs. Mr. O’Bryan has more than 25 years of regulatory experience including biologics, gene therapy and medical devices, most recently serving as vice president of regulatory affairs and quality assurance at Lysogene where he led all aspects of global regulatory affairs. Prior to Lysogene, he was senior director of regulatory affairs at Bluebird bio, where he served as regulatory strategist for CNS programs. Additionally, he built and led the CMC regulatory affairs group across all programs including CNS, hematology and oncology. Prior to Bluebird bio, he served as a global regulatory lead for the cell therapy and regenerative medicine division at Sanofi/Genzyme. Sean holds a B.S. in biology and analysis and policy from Boston University and is regulatory affairs professionals (RAPs) certified.

Sean O’Bryan — Senior Vice President, Regulatory Affairs


Eleven Times Square, 33rd Floor
New York, NY 10036
United States

+1-833-AXOVANT (1-833-296-8268)

  • Axovant Gene Therapies LinkedIn
  • Axovant Gene Therapies Twitter
  • Axovant Gene Therapies Facebook


Viaduktstrasse 8
4051 Basel